An Evidence Gap Analysis is commonly used in the life sciences industry to optimize product development, approval, and marketing of new products.
An Omni-HC evidence gap analysis is a systematic process that assesses the healthcare market's needs to identify gaps between the current evidence base of a product and the requirements for optimized product fit with healthcare stakeholders. Our evidence gap analysis examines the current state of product evidence and it’s fit within the market. This comprehensive analysis informs decisions intended to improve or optimize the product fit.
Omni-HCs approach not only identifies the evidence gaps but also identifies the potential lost value from the gap and defined strategies that will address the data gaps. Our strategies often include the identification of areas where additional research (e.g., sub-analysis) is needed, developing new clinical trials, conducting systematic reviews of existing literature, and generating real-world data.
The goal of an evidence gap analysis is to deliver a comprehensive analysis of the existing and planned data, solutions to fill the gaps, and a projected increase in value from the data generation effort.
Omni-HCs approach not only identifies the evidence gaps but also identifies the potential lost value from the gap and defined strategies that will address the data gaps. Our strategies often include the identification of areas where additional research (e.g., sub-analysis) is needed, developing new clinical trials, conducting systematic reviews of existing literature, and generating real-world data.
The goal of an evidence gap analysis is to deliver a comprehensive analysis of the existing and planned data, solutions to fill the gaps, and a projected increase in value from the data generation effort.